¼¼°èÀÇ Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå : Á¦Ç° À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Glucose Biosensors Market, By Product Type, By Technology, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1808840
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 386 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,595,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,575,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,989,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 97¾ï 8,956¸¸ ´Þ·¯·Î 2025-2032³â¿¡ °ÉÃÄ CAGR 8.7%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀº ÁÖ·Î ´ç´¢º´ °ü¸®¸¦ À§ÇØ Ç÷´ç ¼öÄ¡¸¦ °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â µ¥ »ç¿ëµÇ´Â ±â±â¿¡ ÁÖ·ÂÇÏ´Â ÀÇ·á ¹× Áø´Ü »ê¾÷ÀÇ ÇÑ ºÎ¹®À» ÀǹÌÇÕ´Ï´Ù. Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­´Â »ý¹°ÇÐÀû ¿ä¼Ò(È¿¼Ò µî)¿Í ¹°¸®È­ÇÐÀû °¨Áö±â¸¦ °áÇÕÇÏ¿© Ç÷´ç ¼öÄ¡¸¦ Á¤È®È÷ ÃøÁ¤ÇÏ´Â ºÐ¼® µµ±¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼¾¼­´Â ÀÓ»ó ¹× °¡Á¤¿ë Æ÷µµ´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ¸ðµÎ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇϸç, ȯÀÚÀÇ Ç÷´çÀ» Àû½Ã¿¡ °¨ÁöÇϰí Á¶ÀýÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

±â¼úÀû ¹ßÀüÀ¸·Î ¼¾¼­ÀÇ °¨µµ, ¹ÝÀÀ ½Ã°£ ¹× »ç¿ë ÆíÀǼºÀÌ »ó´çÇÑ °³¼±ÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼­´Â ÀϹÝÀûÀ¸·Î ¿¬¼Ó Ç÷´ç ¸ð´ÏÅÍ(CGM) ¹× ÀÚ°¡ Ç÷´ç ÃøÁ¤±â(SMBG)¿Í °°Àº ÀåÄ¡¿¡ ÅëÇյ˴ϴÙ. ´ç´¢º´ À¯º´·ü Áõ°¡, Ç÷´ç ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í, ºñħ½ÀÀû ¹× ¿þ¾î·¯ºí ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÏ´Â ÇÙ½É ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ ³ª³ë±â¼ú Çõ½Å°ú µðÁöÅÐ Çコ ÅëÇÕ(½º¸¶Æ®Æù ¾Û µî)Àº ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ´õ¿í È®´ëµÇ´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ¿¹¹æ ÀÇ·á¿Í ¿ø°Ý ¸ð´ÏÅ͸µÀ» °­Á¶ÇÔ¿¡ µû¶ó, Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀº ¼±Áø±¹°ú °³¹ßµµ»ó±¹ ¸ðµÎ¿¡¼­ Áö¼ÓÀûÀÎ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Æ÷µµ´ç ¹ÙÀÌ¿À ¼¾¼­ ½ÃÀå - ½ÃÀå ¿ªÇÐ

ºñħ½ÀÀûÀ̰í ÅëÁõÀÌ ¾ø´Â Æ÷µµ´ç ¸ð´ÏÅ͸µ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

ºñħ½ÀÀûÀ̰í ÅëÁõÀÌ ¾ø´Â Æ÷µµ´ç ¸ð´ÏÅ͸µ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø ¿äÀÎÀÔ´Ï´Ù. ±âÁ¸ÀÇ ¼Õ°¡¶ô äÇ÷ ¹æ½ÄÀº ÅëÁõÀÌ ÀÖ°í ºÒÆíÇÏ¿©, ƯÈ÷ ¾î¸°ÀÌ¿Í ºó¹øÇÑ °Ë»çÀÚ »çÀÌ¿¡¼­ ȯÀÚ ¼øÀÀµµ°¡ ³·½À´Ï´Ù. ±¤ÇÐ ¼¾¼­, ¶¡ ±â¹Ý ¸ð´ÏÅÍ, °æÇÇ ÆÐÄ¡¿Í °°Àº ºñħ½ÀÀû ´ë¾ÈÀº ´õ Æí¾ÈÇÏ°í »ç¿ëÀÚ Ä£È­ÀûÀÎ °æÇèÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ¹Ù´Ã ¾øÀÌ ¹ø°Å·Î¿ò ¾øÀÌ ½Ç½Ã°£ Ç÷´ç ÃßÀûÀ» ¿øÇÏ´Â ´ç´¢º´ ȯÀÚ¸¦ ²ø¾îµéÀÔ´Ï´Ù.

°Ô´Ù°¡ ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­¿Í AI¸¦ Ȱ¿ëÇÑ ºÐ¼®ÀÇ Áøº¸´Â Á¤¹Ðµµ¿Í »ç¿ëÀÇ ¿ëÀ̼ºÀ» Çâ»ó½ÃÄÑ Ã¤ÅÃÀ» ´õ¿í µÞ¹ÞħÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú¿¡ ÅõÀÚÇÏ´Â ±â¾÷Àº °æÀï ¿ìÀ§¸¦ ¾ò°í, °Ç°­ °ü¸® ½Ã½ºÅÛÀº ȯÀÚÀÇ °á°ú °³¼±¿¡¼­ ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ´ç´¢º´ÀÇ À¯º´·üÀÌ ¼¼°èÀûÀ¸·Î »ó½ÂÇÏ´Â °¡¿îµ¥ °íÅë ¾ø´Â ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀ¸·ÎÀÇ ÀüȯÀÌ ½ÃÀå ¼ºÀå°ú Çõ½ÅÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

Æ÷µµ´ç ¹ÙÀÌ¿À ¼¾¼­ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®

¼¼°èÀÇ Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀº Á¦Ç° À¯Çü, ±â¼ú, ¿ëµµ, ±â¼ú, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çü¿¡ µû¶ó Àü±âÈ­ÇÐÀû ¹ÙÀÌ¿À¼¾¼­, ±¤ÇÐ ¹ÙÀÌ¿À¼¾¼­ µî ¼¼ °¡Áö ¹üÁÖ·Î ±¸ºÐµË´Ï´Ù. Àü±âÈ­ÇÐÀû ¹ÙÀÌ¿À¼¾¼­´Â ³ôÀº Á¤È®µµ, ½Å·Ú¼º ¹× ´ç´¢º´ °ü¸®¿¡¼­ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ¸·Î ÀÎÇØ °¡Àå Å« Á¡À¯À²À» ±â·ÏÇÏ¸ç Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀ» ÁÖµµÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼¾¼­´Â Æ÷µµ´ç »êÈ­È¿¼Ò¿Í °°Àº È¿¼Ò¸¦ »ç¿ëÇÏ¿© Ç÷´ç ¼öÄ¡¿¡ ºñ·ÊÇÏ´Â Àü±â ½ÅÈ£¸¦ ±â·ÏÇϹǷΠÇ÷´ç ÃøÁ¤±â¿Í ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛ¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. Àú·ÅÇÑ ºñ¿ë, È޴뼺 ¹× ºü¸¥ ¹ÝÀÀ ½Ã°£À¸·Î ÀÎÇØ °³ÀÎ ¹× ÀÓ»ó¿ë ¸ðµÎ¿¡¼­ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ¾ú½À´Ï´Ù.

±¤ÇÐ ¹ÙÀÌ¿À¼¾¼­´Â ºñħ½ÀÀû ¸ð´ÏÅ͸µ°ú °°Àº ÀåÁ¡À» Á¦°øÇÏÁö¸¸, ³ôÀº ºñ¿ë, º¹À⼺, Á¦ÇÑµÈ »ó¿ëÈ­ µîÀÇ °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. µ¦½ºÄÞ(Dexcom)°ú ¾Öº¸Æ®(Abbott)¿Í °°Àº ¼±µµ ±â¾÷µéÀº ÁÖ·Î Àü±âÈ­ÇÐÀû ±â¼úÀ» »ç¿ëÇϸç, ÀÌ´Â ±×µéÀÇ Áö¹è·ÂÀ» ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î, °ËÁõµÈ ¼º´É°ú ½Ç½Ã°£ Æ÷µµ´ç ÃßÀû¿¡ ´ëÇÑ °­·ÂÇÑ ¼ö¿ä¿¡ ÀÇÇØ ÃËÁøµÇ¸é¼­ Àü±âÈ­ÇÐÀû ¹ÙÀÌ¿À¼¾¼­´Â ¿©ÀüÈ÷ ¾÷°è Ç¥ÁØÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ±â¼ú¿¡ µû¶ó È¿¼ÒÇü ¹ÙÀÌ¿À¼¾¼­¿Í ºñÈ¿¼ÒÇü ¹ÙÀÌ¿À¼¾¼­ µÎ °¡Áö ¹üÁÖ·Î ±¸ºÐµË´Ï´Ù. È¿¼ÒÇü ¹ÙÀÌ¿À¼¾¼­´Â È®¸³µÈ ±â¼ú°ú ¿ì¼öÇÑ Æ¯À̼ºÀ¸·Î ÀÎÇØ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» ±â·ÏµÇ¸ç Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀ» ÁÖµµÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¼¾¼­´Â Æ÷µµ´ç »êÈ­È¿¼Ò(GOx)³ª Æ÷µµ´ç Å»¼ö¼ÒÈ¿¼Ò(GDH)¿Í °°Àº È¿¼Ò¸¦ Ȱ¿ëÇÏ¿© Æ÷µµ´ç »êÈ­¸¦ Ã˸ÅÇÔÀ¸·Î½á ¸Å¿ì Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ÃøÁ¤°ªÀ» »ý¼ºÇÕ´Ï´Ù. À̵éÀº ÇΰŽºÆ½ Ç÷´ç ÃøÁ¤±â¿Í ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛ¿¡ ³Î¸® äÅÃµÇ¾î ´ç´¢º´ °ü¸®ÀÇ Ç¥ÁØÀ¸·Î ÀÚ¸®Àâ¾Ò½À´Ï´Ù.

ºñÈ¿¼ÒÀû ¹ÙÀÌ¿À¼¾¼­´Â ´õ ±ä À¯Åë±âÇѰú ȯ°æ ¿äÀο¡ ´ëÇÑ °¨ÃàµÈ ¹Î°¨µµ µîÀÇ ÀåÁ¡À» Á¦°øÇÏÁö¸¸, ÇöÀç È¿¼ÒÀû ¼Ö·ç¼Ç°ú µ¿ÀÏÇÑ ¼öÁØÀÇ ÀÓ»ó °ËÁõ ¹× »ó¾÷Àû ¼º¼÷µµ¸¦ °®ÃßÁö ¸øÇϰí ÀÖ½À´Ï´Ù. ¾Öº¸Æ®(Abbott), µ¦½ºÄÞ(Dexcom), ·Î½´(Roche)¸¦ Æ÷ÇÔÇÑ ÁÖ¿ä Á¦Á¶»çµéÀº ÀÔÁõµÈ ¼º´É°ú ±ÔÁ¦ ±â°üÀÇ ÀÎÁ¤À» ¹Þ¾Æ ÁÖ·Î È¿¼ÒÀû ±â¼úÀ» »ç¿ëÇÕ´Ï´Ù.

Æ÷µµ´ç ¹ÙÀÌ¿À ¼¾¼­ ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

ºÏ¹Ì Áö¿ªÀº ³ôÀº ´ç´¢º´ À¯º´·ü, °í±Þ ÀÇ·á ÀÎÇÁ¶ó, Çõ½Å ±â¼úÀÇ °­·ÂÇÑ µµÀÔÀ¸·Î Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀ» ÃËÁøÇÕ´Ï´Ù. ¹Ì±¹Àº Á¦2Çü ´ç´¢º´ »ç·Ê Áõ°¡, ºñ¸¸À² »ó½Â, ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÃÖ´ë Á¡À¯À²À» ±â·ÏÇÕ´Ï´Ù. ´ç´¢º´ ±â±â¿¡ ´ëÇÑ ¸ÞµðÄÉ¾î ¹× ¸ÞµðÄÉÀÌµå º¸Àå °°Àº Á¤ºÎ Á¤Ã¥ÀÌ ½ÃÀå ¼ºÀåÀ» Ãß°¡·Î µÞ¹ÞħÇÕ´Ï´Ù.

¹Ì±¹Àº ³ôÀº ´ç´¢º´ À¯º´·ü, °í±Þ ÀÇ·á ÀÎÇÁ¶ó, Çõ½ÅÀûÀÎ ¸ð´ÏÅ͸µ ±â¼úÀÇ °­·ÂÇÑ µµÀÔ¿¡ ÃËÁøµÇ¾î Àü ¼¼°è Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. 3,700¸¸ ¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀÌ ´ç´¢º´À» ¾Î°í ÀÖ¾î CGM(¿¹ : µ¦½ºÄÞ G7, ¾Öº¸Æ®ÀÇ ÇÁ¸®½ºÅ¸ÀÏ ¸®ºê·¹)°ú °°Àº Á¤È®ÇÏ°í ½Ç½Ã°£ Æ÷µµ´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä´Â ¿©ÀüÈ÷ °ß°íÇÕ´Ï´Ù. ¹Ì±¹ ½ÃÀåÀº ´ç´¢º´ ±â±â¿¡ ´ëÇÑ ¸ÞµðÄÉ¾î ¹× ¹Î°£ º¸Çè Àû¿ëÀÌ À¯¸®ÇÏ¿© Á¢±Ù¼ºÀ» Çâ»ó½ÃŰ´Â ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù.

Æ÷µµ´ç ¹ÙÀÌ¿À ¼¾¼­ ½ÃÀå - °æÀï ±¸µµ

Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀåÀº ±âÁ¸ÀÇ ÀÇ·á±â±â ´ë±â¾÷°ú ´ç´¢º´ Ä¡·áÀÇ ¹ßÀüÀ» ¸ñÇ¥·Î ÇÏ´Â Çõ½ÅÀûÀÎ ½ÅÈï±â¾÷ÀÌ ºÕºñ´Â °æÀïÀÌ ½ÉÇÑ ½ÃÀåÀÔ´Ï´Ù. Abbott(FreeStyle Libre)¿Í Dexcom(G7 CGM)Àº FDA ÀÎÁõÀ» ¹ÞÀº »ç¿ëÀÚ Ä£È­ÀûÀÎ Áö¼Ó Æ÷µµ´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛÀ¸·Î ½ÃÀåÀ» ¼±µµÇÏ¸ç ºê·£µå ·Î¿­Æ¼¿Í º¸Çè Àû¿ëÀ» ÅëÇØ Å« Á¡À¯À²À» ¾ò°í ÀÖ½À´Ï´Ù. Medtronic(Guardian Connect)°ú Roche(Accu-Chek)´Â ÇÏÀ̺긮µå Æó¼â ·çÇÁ ½Ã½ºÅÛ°ú ±âÁ¸ Ç÷´ç ÃøÁ¤±â¿¡¼­ °­·ÂÇÑ °æÀïÀÚ·Î ³²¾Æ ÀÖ½À´Ï´Ù.

Senseonics(Eversense implantable CGM) ¹× Nemaura Medical(sugarBEAT non-invasive patch)°ú °°Àº ½ÅÈï ±â¾÷Àº Àå±âÀûÀÌ°í °íÅ뽺·± ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀ¸·Î ½ÃÀåÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÇÑÆí Ascensia(Contour Next)¿Í Sinocare(AgaMatrix)´Â ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ Àú·ÅÇÑ Ç÷´ç ÃøÁ¤±â ºÎ¹®¿¡¼­ °æÀïÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ »ê¾÷ ¿¬±¸

Á¦5Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀå ¿µÇâ

Á¦6Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå »óȲ

Á¦7Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå : Á¦Ç° À¯Çüº°

Á¦8Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå : ±â¼úº°

Á¦9Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå : ¿ëµµº°

Á¦10Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ½ÃÀå : Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§Àû Àü¸Á

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Glucose Biosensors Market size was valued at US$ 9,789.56 Million in 2024, expanding at a CAGR of 8.7% from 2025 to 2032.

The Glucose Biosensors Market refers to the segment of the healthcare and diagnostics industry that focuses on devices used to detect and monitor glucose levels, primarily for managing diabetes. Glucose biosensors are analytical tools that combine a biological element (like enzymes) with a physicochemical detector to measure blood sugar levels accurately. These sensors play a crucial role in both clinical and home-based glucose monitoring systems, ensuring timely detection and control of blood glucose in patients.

Technological advancements have significantly improved sensor sensitivity, response time, and ease of use. Biosensors are commonly integrated into devices like continuous glucose monitors (CGMs) and self-monitoring blood glucose (SMBG) meters. The growing prevalence of diabetes, increasing awareness about glucose monitoring, and rising demand for non-invasive and wearable monitoring solutions are key factors fueling market growth. Moreover, innovations in nanotechnology and digital health integration (like smartphone apps) have further expanded the market's potential. As healthcare systems worldwide emphasize preventive care and remote monitoring, the glucose biosensors market is expected to see continuous growth across both developed and developing nations.

Glucose Biosensors Market- Market Dynamics

Growing demand for non-invasive, pain-free glucose monitoring technologies.

The growing demand for non-invasive, pain-free glucose monitoring technologies is a key driver for the glucose biosensors market. Traditional fingerstick methods are painful and inconvenient, leading to poor patient compliance, especially among children and frequent testers. Non-invasive alternatives, such as optical sensors, sweat-based monitors, and transdermal patches, offer a more comfortable and user-friendly experience. These innovations attract diabetic patients seeking hassle-free, real-time glucose tracking without needles.

Additionally, advancements in wearable biosensors and AI-powered analytics enhance accuracy and usability, further boosting adoption. Companies investing in these technologies gain a competitive edge, while healthcare systems benefit from improved patient outcomes. As diabetes prevalence rises globally, the shift toward painless monitoring solutions is accelerating market growth and innovation.

Glucose Biosensors Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.7% over the forecast period (2025-2032)

Based on product type segmentation, Electrochemical biosensors was predicted to show maximum market share in the year 2024

Based on Technology segmentation, Enzymatic biosensors was the leading Technology in 2024

Based on Application segmentation, Diabetes Management was the leading Application in 2024

Based on end-user segmentation, Hospitals & Clinics was the leading end-user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Glucose Biosensors Market- Segmentation Analysis:

The Global Glucose Biosensors Market is segmented on the basis of Product Type, Technology, Application, Technology, and Region.

The market is divided into three categories based on product type: Electrochemical Biosensors, Optical Biosensors. Electrochemical biosensors dominate the glucose biosensors market, holding the largest share due to their high accuracy, reliability, and widespread adoption in diabetes management. These sensors use enzymes like glucose oxidase to generate an electrical signal proportional to glucose levels, making them ideal for blood glucose meters and continuous glucose monitoring (CGM) systems. Their low cost, portability, and rapid response time have made them the preferred choice for both personal and clinical use.

While optical biosensors offer advantages like non-invasive monitoring, they face challenges such as higher costs, complexity, and limited commercialization. Leading brands like Dexcom and Abbott primarily use electrochemical technology, further solidifying their dominance. As a result, electrochemical biosensors remain the industry standard, driven by proven performance and strong demand for real-time glucose tracking.

The market is divided into two categories based on Technology: Enzymatic Biosensors, Non-Enzymatic Biosensors. Enzymatic biosensors dominate the glucose biosensors market, accounting for the largest revenue share due to their well-established technology and superior specificity. These biosensors utilize enzymes like glucose oxidase (GOx) or glucose dehydrogenase (GDH) to catalyze glucose oxidation, producing highly accurate and reliable measurements. Their widespread adoption in fingerstick glucometers and continuous glucose monitoring (CGM) systems has made them the gold standard for diabetes management.

While non-enzymatic biosensors offer advantages like longer shelf life and reduced sensitivity to environmental factors, they currently lack the same clinical validation and commercial maturity as enzymatic solutions. Leading manufacturers, including Abbott, Dexcom, and Roche, primarily use enzymatic technology due to its proven performance and regulatory acceptance

Glucose Biosensors Market- Geographical Insights

The North America region dominates the glucose biosensors market, driven by high diabetes prevalence, advanced healthcare infrastructure, and strong adoption of innovative technologies. The U.S. holds the largest share due to rising type 2 diabetes cases, increasing obesity rates, and growing demand for continuous glucose monitoring (CGM) systems. Government initiatives, such as Medicare and Medicaid coverage for diabetic devices, further support market growth.

The United States dominates the global glucose biosensors market, driven by its high diabetes prevalence, advanced healthcare infrastructure, and strong adoption of innovative monitoring technologies. With over 37 million Americans living with diabetes, demand for accurate, real-time glucose monitoring systems like CGMs (e.g., Dexcom G7, Abbott's FreeStyle Libre) remains robust. The U.S. market benefits from favorable Medicare and private insurance coverage for diabetic devices, enhancing accessibility.

Glucose Biosensors Market- Competitive Landscape:

The glucose biosensors market features a highly competitive landscape, dominated by established medical device giants and innovative startups racing to advance diabetes care. Abbott (FreeStyle Libre) and Dexcom (G7 CGM) lead the market with their FDA-approved, user-friendly continuous glucose monitoring (CGM) systems, capturing significant shares through brand loyalty and insurance coverage. Medtronic (Guardian Connect) and Roche (Accu-Chek) remain strong contenders with hybrid closed-loop systems and traditional glucometers.

Emerging players like Senseonics (Eversense implantable CGM) and Nemaura Medical (sugarBEAT non-invasive patch) are disrupting the market with long-term and painless monitoring solutions. Meanwhile, Ascensia (Contour Next) and Sinocare (AgaMatrix) compete in the affordable blood glucose meter segment, particularly in emerging markets.

Recent Developments:

In June 2024, Abbott announced the CE Mark approval for its next-gen FreeStyle Libre 4 CGM system in Europe, featuring real-time alerts and improved accuracy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GLUCOSE BIOSENSORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL GLUCOSE BIOSENSORS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL GLUCOSE BIOSENSORS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

GLOBAL GLUCOSE BIOSENSORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL GLUCOSE BIOSENSORS MARKET, BY END-USER MARKET ANALYSIS, 2019 - 2032

GLOBAL GLUCOSE BIOSENSORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Glucose Biosensors Market Overview

2. Executive Summary

3. Glucose Biosensors Key Market Trends

4. Glucose Biosensors Industry Study

5. Glucose Biosensors Market: Impact of Escalating Geopolitical Tensions

6. Glucose Biosensors Market Landscape

7. Glucose Biosensors Market - By Product Type

8. Glucose Biosensors Market - By Technology

9. Glucose Biosensors Market - By Application

10. Glucose Biosensors Market - By End-user

11. Glucose Biosensors Market- By Geography

12. Key Vendor Analysis- Glucose Biosensors Industry

13. 360 Degree AnalystView

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â